B.Riley reiterates Cue Biopharma stock rating on allergy data
B.Riley reiterated a Buy rating and $83.00 price target on Cue Biopharma (NASDAQ:CUE) after an event on IgE-mediated diseases. The stock is down 21% this week but up 326% in six months. Analysts highlighted positive data on CUE-221 and its potential compared to omalizumab. The firm sees upcoming data disclosures as key catalysts. Cue Biopharma recently raised $50M and appointed a new Chief Medical Officer. Analysts view the stock as undervalued with targets up to $115.
How this was made
The 30-second read
Why it matters
The combined news may boost short‑term demand for the stock, but execution risk remains.
Market read
Analyst coverage and fresh capital could drive the stock higher, though the impact may be modest.
What to watch
Potential regulatory hurdles for CUE‑221 and competition from established IgE therapies.
Background
Cue Biopharma presented Phase 2 data for CUE‑221 and announced a $50 M private placement, while B.Riley reinstated a Buy rating with an $83 target.
Ticker impact
B.Riley reiterated a Buy rating with an $83 price target and disclosed a recent $50 million private placement, providing fresh capital and analyst coverage for Cue Biopharma.
likely upward pressure as investors price in the higher target and fresh capital.
The private placement adds cash for development and the upgraded coverage signals confidence, but the stock is still far below the target.
Market effects
Positive signal for the biotech sector as a small cap secures sizable financing and analyst endorsement.
Limited to US biotech investors.
Minor, confined to niche allergy‑drug space.
Counterpoint
The $50 M raise could dilute existing shareholders and the price target may be overly optimistic given early‑stage data.
Key entities
- companyCue Biopharma
Biotech firm developing IgE‑targeted therapies.
- analyst_firmB.Riley
Equity research house that issued the rating.
